Synthesis, C-N/N-N bond conformational analysis and evaluation of naphtho[2,3-d][1,2,3]triazole-4,9-dione tethered N-acyl hydrazones as α-amylase inhibitors: Insights from molecular modeling and ADMET analysis
No Thumbnail Available
Date
2025
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
In an effort to expand the repertoire of potent α-amylase inhibitors, we sought to develop novel inhibitors by
combining 1,4-naphthoquinone, 1,2,3-triazole, and N-acyl hydrazone scaffolds in a single matrix. To achieve
this, twelve novel naphtho[2,3-d][1,2,3]triazole-4,9‑dione tethered N-acyl hydrazones were synthesized through
condensation reaction of 2-(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)acetohydrazide with
various substituted aryl aldehydes. Structural elucidation for all the compounds was performed using 1D, 2D-
NMR, FTIR, and mass spectral analyses. The synthesized molecules were evaluated for their ability to inhibit
α-amylase activity using acarbose as the standard drug. All the derivatives exhibited potent inhibition of
α-amylase, with IC50 values ranging between 17.26 ±0.07 to 25.62 ±0.03 μg/mL. Notably, compound 9c
possessing –meta substituted –NO2 group displayed the highest activity (IC50 =17.26 ±0.07 μg/mL) among the
series. Structure-activity relationship (SAR) revealed the pivotal role of aryl ring substitutions in determining
inhibitory efficacy. To validate these findings and to assess the binding stability of 9c within the catalytic site
α-amylase dervied for A. oryzae (PDB ID: 7TAA), in silico studies were performed. The compound 9c effectively
occupies the enzyme’s active pocket, with minimal RMSD fluctuations observed over 100 ns simulation, indi
cating stable protein-ligand complex. ADMET predictions suggested favorable drug-like properties, underscoring
the potential of these compounds as novel α-amylase inhibitors for managing type 2 diabetes mellitus